[Asia Economy Reporter Hyunseok Yoo] RF Bio, a subsidiary of RF Tech, has signed a comprehensive business agreement with Apgujeong Oracle Dermatology Clinic to actively promote research and development of medical aesthetic products and expand market share through mutual cooperation.


RF Bio announced on the 24th that it has signed a comprehensive business agreement with Apgujeong Oracle Dermatology Clinic, following previous partnerships with Okim Plastic Surgery and Banobagi Plastic Surgery.


Through this agreement, RF Bio and Oracle Dermatology Clinic will collaborate to improve the quality of products manufactured by RF Bio and to research and develop next-generation medical aesthetic products. RF Bio plans to receive research and development advice centered on leading beauty medical specialists with outstanding capabilities in the industry.


An RF Bio official stated, "We expect that this agreement will not only strengthen our research capabilities but also increase market share by enhancing brand awareness."


He added, "Dr. Jaeyoung Park, the head of Apgujeong Oracle Dermatology Clinic, has global recognition in anti-aging procedures, to the extent that he is invited to give lectures to leading medical professionals worldwide. Through this business agreement, we expect to raise the brand awareness of RF Bio’s ‘Youthfill’ both domestically and internationally."


A representative from Apgujeong Oracle Dermatology Clinic emphasized, "This business agreement allows us to participate in the research and development process for product development. We plan to collaborate so that Korea’s medical aesthetic technology can be recognized in the global market as well."



RF Bio is a newly established corporation spun off from RF Tech’s bio business division in April. Its main products include the hyaluronic acid (HA) filler ‘Youthfill’ and the anesthetic cream ‘Youthkain.’ Recently, it succeeded for the first time in the world in isolating and identifying botulinum strains from honey, accelerating the development of neurotoxin pharmaceuticals.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing